home.social

#womenshealth — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #womenshealth, aggregated by home.social.

  1. Perimenopause is everywhere. How do you know if you’re in it? – podcast
    By Presented and produced by Madeleine Finlay, with Nicola Davis; sound design by Joel Cox; executive producer Ellie Bury

    Perimenopause has become a hot topic, with celebrities sharing their experiences and doctors offering tips and advice online. But despite the benefits of growing awareness, a rising number of women are now encountering misinformation about treatments such as HRT. Madeleine Finlay hears from Dr Paula Briggs, a consultant in sexual and reproductive health, about why experts have raised the alarm. Science correspondent Nicola Davis gives the facts on symptoms, tests and treatments

    theguardian.com/science/audio/

    #Science #Womenshealth #Contraceptionandfamilyplanning #Society #Health #Menopause #Howtohaveahealthymenopause #Lifeandstyle #TheGuardian #Presented #producedbyMadeleineFinlay #withNicolaDavis #sounddesignbyJoelCox #executiveproducerEllieBury

  2. 'Get a reality check': Cartoon maker refuses to apologise to Jacqui Lambie
    By Alysia Thomas-Sam

    Senator Jacqui Lambie is calling on the One Nation candidate and creator of the party's 'Please Explain' cartoons to drop out of the race for an upper house seat in next month's Victorian election.

    abc.net.au/news/2026-10-26/one

    #OneNation #AI #FederalParliament #WomensHealth #StateandTerritoryElections #AlysiaThomasSam

  3. DATE: October 25, 2026 at 12:00PM
    SOURCE: PSYPOST.ORG

    ** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
    -------------------------------------------------

    TITLE: How the menstrual cycle might alter ADHD symptoms in women taking stimulant medication

    URL: psypost.org/how-the-menstrual-

    The menstrual cycle appears to modulate the severity of attention-deficit/hyperactivity disorder (ADHD) traits in women taking common stimulant medications. A new small study suggests that these traits peak in severity during menstruation and ease soon after, pointing toward a need for hormone-aware treatment plans. The research was published in the Journal of Attention Disorders.

    ADHD is a neurodevelopmental condition characterized by distraction, impulsivity, and hyperactive behavior. Medical professionals historically viewed the condition as something that primarily affected young boys. That diagnostic gap is rapidly closing, and women now make up nearly half of the adult ADHD population in the United States. Women often present with different behavioral patterns than men, leaning toward severe inattention and internalizing behaviors rather than disruptive hyperactivity.

    Despite facing daily impairments in their careers and social lives, women remain largely underrepresented in ADHD research. One distinct biological variable separating women from men is the constant fluctuation of ovarian hormones. During the follicular phase of the menstrual cycle, estrogen levels rise and peak near ovulation. The subsequent luteal phase features elevated estrogen and progesterone, which then drop rapidly shortly before menstruation begins.

    Researchers suspect these hormones play a direct role in brain chemistry. Low estrogen levels are thought to decrease dopamine signaling in the brain. Because dopamine is the primary neurotransmitter involved in focus and attention, these natural hormonal drops could theoretically worsen ADHD symptoms.

    Researchers Rebecca Zaritsky, Stephanie C. Reed, and Suzette M. Evans wanted to understand how these hormonal variations interact with ADHD treatments. Prior laboratory work demonstrated that amphetamines, the most commonly prescribed class of ADHD medications, can be less effective during the luteal phase of the cycle. Case reports from clinical settings also hinted that some women experience worsening moods and fading concentration right before their periods.

    The research team designed a study to track these daily changes prospectively. The investigators recruited participants through online advertisements to monitor their daily experiences. They screened for individuals between the ages of 18 and 40 who experienced regular menstrual cycles lasting between 21 and 35 days.

    To join the study, participants had to report an ADHD diagnosis and currently use amphetamine salts (commonly known by brand names like Adderall) for treatment on at least five days of the week. The team excluded anyone taking hormonal birth control, as well as individuals using other psychiatric medications. After exclusions and dropouts, the researchers ended up with a small study of 30 participants who completed the required long-term tracking.

    Each individual filled out an initial survey detailing their medical history, baseline mood, and general impulsive behaviors. Following this baseline assessment, participants completed a daily online survey for 35 consecutive days. This extended timeline ensured the researchers could capture data from one full menstrual cycle for every participant.

    The daily questionnaires asked participants to rate their current ADHD symptoms on a standardized four-point scale. They evaluated 18 distinct symptoms, splitting them equally between inattentive traits and hyperactive-impulsive traits. Participants also rated their daily mood variations on a six-point scale measuring 17 distinct emotional states, and reported their exact medication dosage for the day. Finally, they noted whether they were actively menstruating or spotting.

    The researchers averaged the daily survey responses and grouped them into three specific biological windows. These windows included the first five days of menstruation, the mid-follicular phase shortly after bleeding ends, and the late luteal phase just before the next period begins. Participants reported their most severe ADHD symptoms during the active menstruation phase. In contrast, they experienced comparatively milder symptoms during the mid-follicular phase.

    When researchers separated the specific types of ADHD traits, hyperactive and impulsive behaviors showed variation across the cycle phases, but after adjusting for multiple comparisons this amounted only to a trend rather than a statistically significant difference. Inattentive symptoms also fluctuated, but the differences were not statistically significant. Participants did not report any differences in how much their symptoms generally impaired their daily lives across the different phases.

    Mood tracking revealed a correlation between negative emotions and ADHD symptoms. Participants reported elevated negative moods during both the late luteal and menstruation phases compared to the mid-follicular phase. The individuals who experienced the largest drops in mood during menstruation also reported the greatest increases in ADHD symptoms. This correlation held true for both inattentive and hyperactive traits.

    Daily amphetamine doses remained remarkably steady across the entire cycle. Participants did not instinctively take more medication to compensate for feeling more distracted or hyperactive during their periods. The research team had hypothesized that some participants using flexible dosing regimens might attempt to counteract their worsening symptoms with higher doses. This lack of adjustment might reflect strict prescribing practices, as many doctors do not encourage patients to alter their daily stimulant intake based on their menstrual cycles.

    This research relied entirely on self-reported surveys. The investigators did not measure hormone levels in a laboratory to perfectly confirm each biological phase, opting instead to estimate phases based on reported bleeding days. The small sample size also limited the statistical power of the analysis, meaning the results require verification in larger populations. Because participants taking other psychiatric medications were excluded, the results might not represent individuals managing ADHD alongside conditions such as mood disorders or premenstrual dysphoric disorder.

    The study design carried a few distinct demographic and methodological limitations. The researchers did not explicitly gather information on gender identity, meaning the relationship between gender identity, hormone cycles, and ADHD remains untested in this specific context. The standardized survey tool used to track daily symptoms was also based on older diagnostic criteria. This older framework lacks recent diagnostic updates designed to capture how ADHD presents in adults.

    The research team also looked at baseline mental health using standardized questionnaires for depression and anxiety. They found a trend suggesting that individuals with higher baseline depression and anxiety scores might experience slightly smaller shifts in ADHD symptoms across their cycles. However, having a higher overall symptom count on average consistently predicted a lower ADHD-related quality of life.

    Future studies will need to incorporate direct hormone sampling to precisely map biological changes to behavioral shifts. Researchers might also explore how oral contraceptives or specific antidepressants impact this hormonal cycle in neurodivergent populations. Some clinics have already begun testing symptom-based dosing regimens, where patients take slightly more medication during the specific weeks when their natural hormones work against them. Tracking these targeted interventions could eventually help doctors provide highly individualized care for women navigating adult ADHD.

    The study, “Changes in ADHD Symptoms and Mood Across the Menstrual Cycle in Females Treated With Stimulants: A Pilot Study,” was authored by Rebecca Zaritsky, Stephanie C. Reed, and Suzette M. Evans.

    URL: psypost.org/how-the-menstrual-

    -------------------------------------------------

    Private, vetted email list for mental health professionals: clinicians-exchange.org

    Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

    -------------------------------------------------

    #psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #ADHD #WomensHealth #MenstrualCycle #ADHDWomen #MentalHealth #Neurodiversity #HormonalHealth #ADHDAwareness #StimulantMedication #HealthResearch

  4. Ethnic minorities in England less likely to get breast cancer diagnosis from routine screening
    By Tobi Thomas Health and inequalities correspondent

    Exclusive: People from marginalised groups more likely to be diagnosed via urgent referral or in emergency setting, research finds

    theguardian.com/society/2026/o

    #Breastcancer #Inequality #Health #Race #Poverty #NHS #England #UKnews #Cancer #Cancerresearch #Womenshealth #TheGuardian #TobiThomasHealth #inequalitiescorrespondent

  5. Greg Wise on how he and Emma Thompson coped with failed IVF: ‘We hit an existential crisis – she was not a proper woman and I was not a proper man’
    By Greg Wise

    Their hopes of having a second child were dashed. Two decades on, the actor remembers the grief and pain of that time

    theguardian.com/lifeandstyle/2

    #Lifeandstyle #Books #IVF #Fertilityproblems #Reproduction #Menshealth #EmmaThompson #Health #Society #Womenshealth #Family #Children #Culture #Film #TheGuardian #GregWise

  6. Darwin patients' medical information posted to Instagram in privacy breach
    By Grace Atta

    Confidential medical information belonging to about a dozen pregnant patients at Royal Darwin Hospital was posted to Instagram by a 'medical observer' associated with the facility.

    abc.net.au/news/2026-10-25/nt-

    #PublicHealth #WomensHealth #DataPrivacy #GraceAtta

  7. DATE: October 24, 2026 at 02:00PM
    SOURCE: PSYPOST.ORG

    ** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
    -------------------------------------------------

    TITLE: Breast reduction surgery is linked to improved sexual function

    URL: psypost.org/breast-reduction-s

    Women who undergo breast reduction surgery often experience improvements in their sexual function, including enhanced desire, arousal, and satisfaction. A recent systematic review and meta-analysis published in The Journal of Sexual Medicine evaluated previous research to better understand how altering breast size influences sexual well-being. The combined data suggest that both physical relief and psychological shifts contribute to a better sexual experience after the procedure.

    Breast reduction, medically known as reduction mammoplasty, is one of the most common aesthetic and therapeutic surgeries performed globally. The procedure involves removing excess skin, fat, and glandular tissue to create smaller, more proportionate breasts. Women often seek the surgery to alleviate the physical burdens of having very large breasts, a condition called macromastia. These physical burdens can include chronic back and shoulder pain, skin irritation, and difficulty exercising.

    Beyond physical discomfort, excessively large breasts can impact a person’s mental health and body image. Breasts are closely associated with femininity and sexual identity in many cultures. Deviation from societal standards regarding breast size can sometimes lead to psychological distress, low self-esteem, and sexual health challenges. Women may feel self-conscious during intimacy, an internal distraction that can hinder sexual arousal and satisfaction.

    While many patients pursue breast reduction hoping to improve their sexual life, previous research on the topic has produced conflicting results. Some studies have reported positive impacts on sexual desire and body image. Other studies found no measurable changes in sexual satisfaction compared to women who did not undergo the surgery.

    To clarify these mixed results, a team of researchers based in Iran led the current investigation. The team included Mahdiye Taheri, Zahra Ghorbani, Fatemeh Alavi-Arjas, Maryam Firouzabadi, and Hamid Alavi Majd. They set out to systematically evaluate and synthesize the existing data on how breast reduction affects postoperative sexual function.

    The researchers conducted a comprehensive search of medical databases to identify studies published up to April 2025. They specifically looked for original, English-language articles that quantitatively assessed sexual function in women after breast reduction surgery. They excluded studies focusing on breast surgeries performed for cancer treatment or gender affirmation. This exclusion kept the focus strictly on healthy women with symptomatic macromastia, avoiding the overlapping psychological effects of cancer or gender dysphoria.

    Their search yielded 13 eligible studies containing data from 676 participants. The studies took place across several countries, including Brazil, Turkey, the United Kingdom, the United States, Italy, Iran, Poland, and Spain.

    The review revealed that nine of the 13 studies documented an improvement in sexual function after surgery. Four of the studies reported no notable changes. Many of the included studies used the Female Sexual Function Index, a standardized questionnaire designed to measure domains such as sexual desire, physiological arousal, lubrication, orgasm, satisfaction, and pain. Across the research, women frequently reported enhancements in almost all of these categories following their operations.

    For example, one study included in the review found that the percentage of women experiencing clinical sexual dysfunction dropped from 62.5 percent before the surgery to 21.4 percent afterward. Another prospective study conducted in the United States demonstrated an improvement in sexual function in over 68 percent of the women tracked.

    Because eight of the studies used similar standardized instruments, the researchers were able to perform a meta-analysis. A meta-analysis combines the statistical data from multiple independent studies to identify overall trends. This combined analysis demonstrated that breast reduction was associated with a 13.27 percent increase in the mean score of sexual function among patients.

    The researchers identified several physiological pathways that might explain these outcomes. On a physical level, reducing the volume of the breast can alleviate chronic pain and physical restrictions. This relief removes persistent physical discomfort that can act as a sensory distraction during sexual arousal.

    Some evidence also suggests that removing excess tissue can normalize the distribution of sensory nerves in the breast. The nipple-areola complex is heavily innervated and plays a role in triggering the release of oxytocin, a hormone involved in arousal and emotional bonding. Modern surgical techniques aim to preserve these neural pathways, maintaining the physical triggers required for a full sexual response.

    Psychologically, the surgery often leads to a reevaluation of body image. Women with large breasts frequently experience “spectatoring,” a cognitive process where attention is diverted from erotic sensation toward continuous self-monitoring of their appearance. This self-surveillance can induce performance anxiety and diminish sensory engagement.

    By alleviating appearance-related anxiety, breast reduction allows individuals to engage more fully in sexual experiences. This psychological shift creates a positive feedback loop. Enhanced body image facilitates sexual satisfaction, and positive sexual experiences then reinforce a more cohesive self-concept and better global self-esteem.

    The researchers noted that mental health benefits extend beyond the bedroom. One large database study cited by the researchers in their discussion reported that prescriptions for certain antidepressant and anti-anxiety medications dropped from 46.3 percent to 29.5 percent among patients following breast reduction. This alleviation of psychological distress likely establishes a stronger mental foundation for sexual desire.

    Partner reactions also play a role in postoperative sexual well-being. Positive reactions from a partner regarding the physical changes can enhance the sexuality-promoting effects of the surgery. Conversely, criticism or neutral reactions can undermine the potential benefits. One study demonstrated that improvements in female sexual function after the operation were accompanied by an increase in their partners’ own sexual function scores.

    While the combined data indicate a positive association between breast reduction and sexual function, the results rely primarily on observational studies. Observational research can identify links between variables but cannot definitively prove that the surgery directly caused the improvements in sexual function.

    The individual studies included in the review often featured small sample sizes, typically involving fewer than 50 participants. Most of the research also relied on brief follow-up periods, usually checking in with patients just three to six months after their operations. This short timeframe limits the ability to determine if the sexual and psychological benefits persist over the long term or if delayed complications arise later.

    The studies varied widely in their design and the surgical techniques used. The available data did not allow the researchers to measure how specific factors, such as the exact volume of tissue removed or the specific surgical methods employed, influenced the final sexual outcomes. Future research will need to record these surgical parameters to help doctors provide personalized advice to patients regarding nerve preservation and physical sensation.

    Future studies would also benefit from evaluating more diverse populations. The current body of literature focuses almost entirely on cisgender, heterosexual women. Expanding this research to include LGBTQ+ individuals and women from a wider variety of cultural and socioeconomic contexts would provide a more comprehensive understanding of how breast reduction affects sexual well-being across different demographics.

    The study, “Sexual function following reduction mammoplasty: a systematic review and meta-analysis,” was authored by Mahdiye Taheri, Zahra Ghorbani, Fatemeh Alavi-Arjas, Maryam Firouzabadi, and Hamid Alavi Majd.

    URL: psypost.org/breast-reduction-s

    -------------------------------------------------

    Private, vetted email list for mental health professionals: clinicians-exchange.org

    Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

    -------------------------------------------------

    #psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #BreastReduction #ReductionMammoplasty #SexualHealth #WomensHealth #PlasticSurgery #BodyImage #MentalHealth #PatientWellness #MedicalResearch #HealthResearch

Share on Mastodon

Enter the server where you have an account.